HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Finds ‘Unacceptable’ Levels Of NDMA In 80% of Ranitidine Batches

Executive Summary

Testing carried out by Australia's drug agency on batches of 34 ranitidine products marketed by 10 different sponsors has found high levels of NDMA contamination in the vast majority of cases. The agency is now considering tightening its oversight of all ranitidine drugs sold in Australia. 

You may also be interested in...



Australia Suspends 23 Ranitdine Products Contaminated with NDMA

A six-month suspension from sale has been handed to 23 ranitidine drugs sold in Australia. The country's regulator has suggested all 23 are facing a permanent ban over patient safety fears.

EU Guidance Assists With Nitrosamine Evaluations

The EU guide covers medicines authorized at the national level and under the mutual recognition and decentralized procedures.

EU Offers Practical Guide To Help Pharma With Nitrosamine Evaluations

The EU guide covers medicines authorized at the national level and under the mutual recognition and decentralized procedures.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS149356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel